Several reports have described a combination treatment approach with PD‐L1/PD‐1‐targeted therapy, including ibrutinib and nivolumab in non‐Hodgkin lymphoma (NHL)9 and chronic lymphocytic leukemia (CLL) and lenalidomide with pembrolizumab in double‐hit lymphoma.10 Here, CD274 is linked to lymphoma.